Amgen 4Q profit rises 1 percent with sales steady
Amgen reports mixed 4Q results for anemia drugs but says revenue from other drugs was stable

(PressMethod) - Biotechnology company Amgen Inc. said Monday its profit rose 1 percent in the fourth quarter, as the company reported mixed results for its anemia drugs, but said sales of its other drugs held steady.

Sales of one of Amgen's anemia drugs, Aranesp, sank after research linked it to an increased risk of stroke in some patients. But sales of Epogen, its other anemia drug, improved due to an increase in potential patients, use of larger doses, and higher sales prices. Sales of both have been under pressure to previous safety concerns.

Total sales of Amgen's Aranesp and Epogen, which are used to treat anemia in chemotherapy patients and patients on kidney dialysis, held steady at $1.35 billion. Amgen said sales of its drugs Neulasta and Neupogen, which are used to prevent infections in chemotherapy patients, rose 2 percent to $1.2 billion.

The Thousand Oaks, Calif., company says profit rose to $931 million, or 92 cents per share, from $925 million, or 87 cents per share. Excluding one-time items, profit fell 5 percent to $1.05 per share. Revenue grew 2 percent, to $3.81 billion from $3.75 billion.

CONTACT INFORMATION

Email Us

http://

###

Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PressMethod. We will be unable to assist you with your inquiry. PressMethod disclaims any content contained in these release.